Merck Reverses 2 Day Surcharge Policy After Tariff Breakthrough Between China and US

In a surprising turnaround, Merck Life Science has officially canceled a temporary surcharge on Chinese orders just two days after its implementation. On May 11, Merck announced that due to escalating tariffs, all shipments to China would incur additional fees starting May 12. However, following a May 12 joint statement between China and the US, which significantly eased the trade tensions, Merck rescinded the policy on May 14, citing the “positive consensus” reached by both nations.

The temporary surcharge—active for only 48 hours—sparked immediate concern among Chinese research institutions and biopharma companies, many of which rely heavily on Merck’s molecular biology kits, PCR reagents, and cell culture media. These materials are vital for diagnostics, R&D, and drug manufacturing. An extended price hike would have directly impacted domestic firms like Mindray and New Industries Biomedical, pushing up production costs and squeezing profit margins.

Had the tariff situation persisted, some smaller labs might have been forced to cut back on projects due to budget constraints, threatening scientific progress. The brief implementation of the fee was a wake-up call for many Chinese buyers, who are now reconsidering their supply chains and exploring local alternatives to reduce long-term risk.

This episode highlights the fragile balance between global trade policy and scientific innovation. For Merck, quick policy adjustments reflect a pragmatic approach to a fluid geopolitical landscape. For China’s life sciences sector, it may mark the beginning of a push for greater domestic self-sufficiency in critical raw materials.